Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey

BMC Cancer

Yuko Kodama³  Ryoko Morozumi²  Tomoko Matsumura³  Yukiko Kishi³  Naoko Murashige³  Yuji Tanaka³  Morihito Takita³  Nobuyo Hatanaka³  Eiji Kusumi³  Masahiro Kami³  Akihiko Matsui¹ 

[1] Faculty of Economics, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan

[2] Faculty of Economics, University of Toyama, 3190 Gakufu, Toyama-shi, Toyama, 930-8555, Japan

[3] Division of Social Communication System for Advanced Clinical Research, the Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan

关键词: Health insurance;    Anticancer drug;    Hematology;    Economic recession;   

Others  :  1080455
DOI  :  10.1186/1471-2407-12-152

 received in 2011-12-02, accepted in 2012-04-24,  发布年份 2012

【 授权许可】

   
2012 Kodama et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mason A, Drummond M, Ramsey S, Campbell J, Raisch D: Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol 2010, 28:3234-3238.
• [2]Mileshkin L, Schofield PE, Jefford M, Agalianos E, Levine M, Herschtal A, Savulescu J, Thomson JA, Zalcberg JR: To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option. J Clin Oncol 2009, 27:5830-5837.
• [3]Wolfe F, Michaud K: Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61:1563-1570.
• [4]Ikegami N, Yoo BK, Hashimoto H, Matsumoto M, Ogata H, Babazono A, Watanabe R, Shibuya K, Yang BM, Reich MR, Kobayashi Y: Japanese universal health coverage:evolution, achievements, and challenges. Lancet 2011, 378:1106-1115.
• [5]Shiroiwa T, Fukuda T, Tsutani K: Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. Int J Clin Oncol 2010, 15:256-262.
• [6]Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
• [7]Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
• [8]Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
• [9]Sakai M, Miyazaki Y, Matsuo E, Moriuchi Y, Hata T, Fukushima T, Imaizumi Y, Imanishi D, Taguchi J, Iwanaga M, Tsushima H, Inoue Y, Takasaki Y, Tsuchiya T, Komoda M, Ando K, Horio K, Moriwaki Y, Tominaga S, Itonaga H, Nagai K, Tsukasaki K, Tsutsumi C, Sawayama Y, Yamasaki R, Ogawa D, Kawaguchi Y, Ikeda S, Yoshida S, Onimaru Y, et al.: Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol 2009, 89:319-325.
• [10]Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Dobrez DG, Hensley ML, Cella D, IRIS Investigators: Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003, 21:2138-2146.
• [11]Thompson Healthcare: Red Book: Pharmacy’s Fundamental Reference. Montvale, NJ: Thompson Healthcare; 2008.
• [12]Bennett MI, Closs SJ, Chatwin J: Cancer pain management at home (I): do older patients experience less effective management than younger patients? Support Care Cancer 2009, 17:787-792.
• [13]Ministry of Internal Affairs and Communications, Government of Japan: [http://www.stat.go.jp/english/data/sousetai/es08.htm] webciteAnnual report on the family income and expenditure survey. 2008.
• [14]Kelley RK, Venook AP: Nonadherence to imatinib during an economic downturn. N Engl J Med 2010, 363:596-598.
• [15]Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J: Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007, 25:481-496.
• [16]U.S. Department of Health and Human Services: [http://aspe.hhs.gov/poverty/09poverty.shtml] webciteThe 2009 HHS Poverty Guidelines. 2009.
• [17]Ministry of Health, Labour and Welfare, Government of Japan: [http://www.mhlw.go.jp/english/database/db-hss/dl/report_gaikyo_2009.pdf] webciteSummary Report of Comprehensive Survey of Living Conditions. 2009.
• [18]Mehnert A: Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol 2011, 77:109-130.
• [19]Pharmaceutical Medical Devices Agency of Japan: [http://www.info.pmda.go.jp] webciteGlivec Tablets (in Japanese).
• [20]Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, Kweon IY, O’Neil WM, Saikia TK, Wang J: Chronic myeloid leukemia in Asia. Int J Hematol 2009, 89:14-23.
• [21]Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R: European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
• [22]Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
• [23]Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
• [24]Ministry of Health, Labour and Welfare: [http://www.iryohoken.go.jp/shinryohoshu/searchMenu/doSearchInputYp] webciteVarious information of medical fee.
• [25]Kawaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa K, Mitsuya H, Saito H: Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol 2009, 89:642-648.